There were 1,838 press releases posted in the last 24 hours and 399,935 in the last 365 days.

Novitium Pharma Issues Voluntary National Recall of Ranitidine Hydrochloride Capsules 150mg and 300mg Due to an Elevated Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA)

EAST WINDSOR, N.J., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Novitium Pharma LLC (Novitium) is voluntarily recalling all quantities and lots, within expiry, of Ranitidine Hydrochloride Capsules in the US to the consumer level. Ranitidine Hydrochloride Capsules are being recalled because of potential N-Nitrosodimethylamine (NDMA) amounts above levels established by the FDA. To date, Novitium has not received any reports of adverse events related to use of the product as part of this recall.

Risk Statement: NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables. 

Ranitidine Hydrochloride Capsules are indicated for the treatment of duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome, and other conditions where reduction of gastric secretion and acid output is desirable. The affected Ranitidine Hydrochloride Capsule can be identified by NDC numbers stated on the product label. 

Description Strength Type Pack Size NDC
Ranitidine Capsules 150mg 150 mg Rx 60 ct bottle 70954-001-20
Ranitidine Capsules 150mg 150 mg Rx 500 ct bottle 70954-001-40
Ranitidine Capsules 300mg 300 mg Rx 30 ct bottle 70954-002-10
Ranitidine Capsules 300mg 300 mg Rx 100 ct bottle 70954-002-40

Novitium will be notifying its distributors and customers via email and via the Novitium website and will arrange for return of all recalled products. Wholesalers (direct customers) will be asked to immediately stop distribution and return any stock to Novitium by contacting Cardinal Health Specialty Services and contact the retail pharmacies in their group to do the same.  Pharmacies will be asked to immediately stop dispensing Novitium Ranitidine Hydrochloride Capsules and return remaining stock to Novitium by contacting Cardinal Health Specialty Services to request a recall packet.

Consumers are asked to continue taking their medication and speak to their physician or pharmacist about alternate healthcare treatment options.  Consumers, desiring to return product, should contact the pharmacy from which it was purchased. 

Consumers with questions regarding this recall can contact Novitium at: (609) 469-5920 between 8am and 5pm (Monday-Friday) or e-mail:  Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Company Contact:

Navya Jaikumar; Business Development and Customer Service
Phone Number: (609) 469-5920

Primary Logo